Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: Evaluation of Postexposure Antibiotic Prophylaxis
to Prevent Anthrax
In response to the recent bioterrorist attacks associated with intentional release of
Bacillus anthracis, approximately 10,000 persons potentially exposed to anthrax in Connecticut, Florida, New Jersey, New York City, and Washington, D.C.,
were recommended to take at least 60 days of postexposure anti-biotic prophylaxis. Surveillance for adverse events and adherence
to antibiotics has been conducted through surveillance and cross-sectional studies. CDC is evaluating the program to
distribute antimicrobial agents and assessing adverse events and adherence. The objectives of this evaluation are to assess the provision
of antimicrobial agents and educational materials to affected persons, to determine adverse events associated with
the antimicrobial agents, and to characterize adherence to the recommended regimen. The information from this evaluation
will be critical to CDC's effort to improve the technical assistance and supplies needed with future anthrax
postexposure prophylaxis campaigns and to comply with Food and Drug Administration regulations for monitoring for adverse events.
CDC has contracted RTI International to conduct brief telephone interviews of all persons for whom
postexposure antibiotic prophylaxis was recommended. Interviews are scheduled to begin in late January 2002 and will continue
for approximately 8 weeks. Additional information about the program evaluation is available from CDC, telephone
404-639-3158.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
